Skip to main content

CTX

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Mirum Pharmaceuticals
Mirum PharmaceuticalsFOSTER CITY, CA
1 program
Blinded CDCA 250 mg TIDPHASE_31 trial
Active Trials
NCT04270682Completed19Est. Oct 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Mirum PharmaceuticalsBlinded CDCA 250 mg TID

Clinical Trials (1)

Total enrollment: 19 patients across 1 trials

NCT04270682Mirum PharmaceuticalsBlinded CDCA 250 mg TID

Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)

Start: Jan 2020Est. completion: Oct 202319 patients
Phase 3Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.